ArticleNature communications2022
RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation and inflammation partially through CysLT1R.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- RBM protein family: Focusing on the occurrence, progression and treatment of cancer.Medical oncology (Northwood, London, England) · 2026Review
- SEC14L2 contributes to tumor progression by enhancing USP5-driven RBM3 deubiquitination in pancreatic ductal adenocarcinoma.Oncogene · 2026Article
- Group 2 innate lymphoid cells: Where are we 15 years out?The Journal of allergy and clinical immunology · 2026Review
- HuR Regulates GATA3-Driven Type 2 Inflammation in CD4bioRxiv : the preprint server for biology · 2026Article
- RNA-binding motif proteins as context-dependent regulators of tumor-immune crosstalk, genome stability, and therapeutic vulnerabilities in cancer.Frontiers in immunology · 2026Review
- Unraveling cysteinyl leukotrienes and their receptors in inflammation through the brain-gut-lung axis.Virulence · 2025Review
- Update on type 2 immunity.The Journal of allergy and clinical immunology · 2025Review
- Identification of Alzheimer's disease biomarkers and their immune function characterization.Archives of medical science : AMS · 2025Article
- PIP-seq identifies novel heterogeneous lung innate lymphocyte population activation after combustion product exposure.Scientific reports · 2024Article
- Alternative 3'UTR expression induced by T cell activation is regulated in a temporal and signal dependent manner.Scientific reports · 2024Article
- Article
- Rbm3 deficiency leads to transcriptome-wide splicing alterations.RNA biology · 2024Article
- The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases.Frontiers in immunology · 2024Review
- Quantitative multiorgan proteomics of fatal COVID-19 uncovers tissue-specific effects beyond inflammation.EMBO molecular medicine · 2023Article
- Regulation of mRNA stability contributes to the function of innate lymphoid cells in various diseases.Frontiers in immunology · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
19 authors at 6 institutions in 2 countries.
Jana H BadraniDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-6479-7969
Allyssa N StrohmDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Lee LacasaDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-2240-8715
Blake CivelloDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-1503-6028
Kellen CavagneroDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Yung-An HaungDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-3543-7785
Michael AmadeoDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Luay H NajiDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Sean J LundDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-9807-6585
Anthea LengDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Hyojoung KimDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Rachel E BaumDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Naseem KhorramDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Monalisa MondalLa Jolla Institute, La Jolla, CA, USA.
Grégory SeumoisLa Jolla Institute, La Jolla, CA, USA.ORCID 0000-0002-8164-6852
Julie PilotteThe Scripps Research Institute, La Jolla, CA, USA.
Peter W VanderklishThe Scripps Research Institute, La Jolla, CA, USA.
Heather M McGeeDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-3761-5087
Taylor A DohertyDivison of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, USA. tdoherty@ucsd.edu.ORCID 0000-0003-3256-0398
University of California San Diego · USLa Jolla Institute for Immunology · USScripps Research Institute · USChang Gung University · TWSalk Institute for Biological Studies · USUC San Diego Health System · US
Funding
RBM3 regulation of type 2 innate lymphoid cells in allergic inflammationR01AI114585 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOHERTY, TAYLOR A · 2015 to 2019
$2.3MMentoring patient-oriented researchers in inflammatory airway diseaseK24AI171795 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TAYLOR A DOHERTY · 2022 to 2026
$968kInvestigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor MicroenvironmentsR00CA256526 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI MCGEE, HEATHER MICHELLE · 2022 to 2024
$747kInvestigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor MicroenvironmentsK99CA256526 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI MCGEE, HEATHER MICHELLE · 2021 to 2021
$137kTargeting pathogenic innate lymphoid cells in airway diseaseI01BX005073 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI TAYLOR A DOHERTY · 2021 to 2026
–BLRD VA I01 BX005073NCI NIH HHS K99 CA256526NCI NIH HHS R00 CA256526NIAID NIH HHS K24 AI171795NIAID NIH HHS R01 AI114585
Abstract
Innate lymphoid cells (ILC) promote lung inflammation in asthma through cytokine production. RNA-binding proteins (RBPs) are critical post-transcriptional regulators, although less is known about RBPs in ILC biology. Here, we demonstrate that RNA-binding motif 3 (RBM3) is highly expressed in lung ILCs and is further induced by alarmins TSLP and IL-33. Rbm3
Indexed as
AsthmaPneumoniaAllergensAnimalsCytokinesImmunity, InnateInflammationInterleukin-33LungLymphocytesMiceReceptors, LeukotrieneRNA-Binding ProteinsAllergensCytokinesInterleukin-33leukotriene D4 receptorRbm3 protein, mouseReceptors, LeukotrieneRNA-Binding Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.